Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05179525 · ClinicalTrials.gov registry record · Phase 1
Comparative Bioavailability of Risperidone.
A Phase 1 study of Schizophrenia, sponsored by Rovi Pharmaceuticals Laboratories.
- Completed
- Registry status
- Phase 1
- Development phase
- 80
- Enrollment target
- 4
- Study locations
NCT05179525: Completed Phase 1 study of Schizophrenia, sponsored by Rovi Pharmaceuticals Laboratories.
NCT05179525 is a Phase 1 study of Schizophrenia that has completed, run by Rovi Pharmaceuticals Laboratories. The registered enrollment target is 80 participants, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (63% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05179525, a Phase 1 study of Schizophrenia, has completed, sponsored by Rovi Pharmaceuticals Laboratories.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 80 participants
- Enrollment target
- 4
- Study locations
Study Summary
This is an Open-Label, One-Sequence Study to Evaluate the Steady- State Comparative Bioavailability of Intramuscular Risperidone ISM® and EU Risperdal® (Sourced From Germany).
Primary Outcome
Mean steady-state area under the curve during the dosing interval for the active moiety
Conditions Studied
Interventions
- DRUG Risperidone ISM® 100 mg
- DRUG Risperdal 4mg Tablet
Study Locations (4)
California
- Collaborative NeuroScience Research, LLC - Garden Grove
Maryland
- CBH Health, LLC - Gaithersburg
New Jersey
- Hassman Research Institute - Berlin
Texas
- Rajinder Shiwach - DeSoto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2021-03-09 |
| Est. Completion | 2021-09-17 |
| Phase | Phase 1 |
What the finished NCT05179525 record still lists
NCT05179525 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 219-participant average among 315 other Schizophrenia trials with a reported enrollment target (63% lower).
The record links to 1 condition, with Schizophrenia appearing as the primary indexed condition, and to 2 interventions - of which Risperidone ISM® 100 mg is the first listed.
NCT05179525 reports a single indexed study location in California, Maryland, New Jersey.
Frequently Asked Questions
What is clinical trial NCT05179525 about?
NCT05179525 is a clinical study titled "Comparative Bioavailability of Risperidone.". This is an Open-Label, One-Sequence Study to Evaluate the Steady- State Comparative Bioavailability of Intramuscular Risperidone ISM® and EU Risperdal® (Sourced From Germany).
What is the current status of trial NCT05179525?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 80 participants. The study started on 2021-03-09. Estimated completion is 2021-09-17.
What conditions does trial NCT05179525 study?
This clinical trial studies the following conditions: Schizophrenia.
What interventions are being tested in trial NCT05179525?
The interventions under investigation include: Risperidone ISM® 100 mg (DRUG), Risperdal 4mg Tablet (DRUG).
Who is sponsoring clinical trial NCT05179525?
This trial is sponsored by Rovi Pharmaceuticals Laboratories, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05179525 being conducted?
This trial has 4 study locations across California, Maryland, New Jersey, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05179525's enrollment target sits among peer trials
80 161st of 315 higher than 151 of 315 other Schizophrenia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Schizophrenia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Tolerability of MDMA in Schizophrenia
RECRUITING · Phase 1
-
Imaging Synapses With [11C] UCB-J in the Human Brain
RECRUITING · Phase 1
-
A Study to Evaluate the Dose Levels, Safety, and Drug Levels of Single KarXT Intramuscular Injection in Participants With Schizophrenia
RECRUITING · Phase 1
-
Proposal To Develop A Rapid And Cost-Effective Diagnostic Test For Schizophrenia
RECRUITING · Phase 1
-
Determining Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar Disorder
RECRUITING · Phase 1
-
Genetics of Cannabis Use Disorder and Cannabinoid Response in Humans
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI